Prostate cancer detected on repeat biopsies have more favorable tumor characteristics but similar recurrence rates

Prostate cancer (CaP) detected on repeat biopsy may reflect smaller volume tumors and less aggressive biological and clinical disease.

Dr. Lopez-Corona and associates at Memorial-Sloan Kettering Cancer Center examined this question in over 1000 patients and found more favorable pathologic tumor characteristics, but similar rates of biochemical recurrence.

Their report appears in the March 2006 issue of the Journal of Urology.

Clinical and pathologic data were collected on 1,357 patients treated with radical prostatectomy by one surgeon (Dr. Scardino) between 1983 and 2001. Clinical stage T1-T2 disease was present in 94% of the cohort. CaP was detected at first biopsy in 1,042 patients (77%), at second biopsy in 227 (17%), at third biopsy in 59(4%) and at fourth or later biopsy in 29(2%).

Men diagnosed at initial biopsy were more likely to have smaller prostates, and abnormal digital rectal examinations. No difference was identified in the number of men diagnosed with a biopsy Gleason sum of 7 or higher regardless at which biopsy the cancer was detected. Of the men diagnosed at initial biopsy, 61% had organ confined CaP compared to 75% of 315 patients diagnosed on two or greater biopsies. Furthermore, extracapsular extension, seminal vesicle invasion, frequency of poorly differentiated tumors and lymph node metastases were higher in men diagnosed on initial biopsy.

Median cancer volume was significantly greater in men diagnosed at first biopsy (2.02cc vs. 1.13cc, respectively). Prostates greater than 50cc in size were more likely to meet the investigators definition of indolent tumors than glands smaller than 50cc in size.

Despite the pathologic differences, the progression-free probability at 5 years was similar (mean 78.7%) regardless of how many biopsies were necessary to detect the CaP.

By Christopher P. Evans, MD


Reference:

J Urol 2006;175:923-928

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16469581&query_hl=1&itool=pubmed_docsum

Lopez-Corona E, Ohori M, Wheeler TM, Reuter VE, Scardino PT, Kattan MW, Eastham JA

UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Researchers identify shared molecular mechanism in cancer and pregnancy that suppresses immune system